Airway diseases
Sleep and breathing disorders
Thoracic oncology
E-poster
Biology of lung cancer: preclinical and translational research
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Methods :
Cell and molecular biology
LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis
S. Behrend(München, Germany)
COI
1
cAMP response element-binding protein mediates immune-evasion of KRAS-mutant lung adenocarcinoma
G. Giotopoulou(Munich, Germany)
COI
2
PARP activity and expression in response to DNA damage in mice with lung cancer-induced cachexia
J. TANG(Barcelona, Spain)
COI
3
Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells
A. Gründing(Hannover, Germany)
COI
4
IGF1R facilitates implantation and progression of lung metastasis acting in the tumor microenvironment
E. Alfaro Arnedo(Logroño (La Rioja), Spain)
COI
5
The inhibition of caspase-11 could prevent lung cancer in smoking mice
C. Colarusso(Fisciano (SA), Italy)
COI
6
LSC - 2021 - Macrophages in lung adenocarcinoma
G. Ntaliarda(Patra, Greece)
COI
7
LSC - 2021 - Preclinical evaluation of IL-1ß inhibition against KRAS-mutant lung adenocarcinoma
G. Skiadas(Patras, Greece)
COI
8
Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs?
S. Wrenger(Hannover, Germany)
COI
9
Lung Cancer Stem Cells From Lymph Nodes Aspirates Express Immunosuppressive Molecules
A. Raniszewska(Warszawa, Poland)
COI
10
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC).
J. Moes-Sosnowska(Warsaw, Poland)
COI
11
Regulation of PA200 in lung cancer
A. Yazgili(München, Germany)
COI
12
Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response
J. Hye Jin(Seoul, Republic of Korea)
COI
13
Evaluation expression of miR-146a and miR-155 and inflammatory cytokines in blood of non-small cell lung cancer patients
N. K.Dezfuli(Tehran, Islamic Republic of Iran)
COI
14
High fold-changes in peripheral blood PD-1+ CD8+ T cells expressing Granzyme B predicts the response to immunotherapy in NSCLC
Y. Kim(Yangsan city (Kyeongsang Nam-do), Republic of Korea)
COI
15
Identifying a tissue specific microRNA molecular signature in lung cancer
A. Harangus(Cluj-Napoca, Romania)
COI
16
Lung cancer biomarkers based on miRNA
M. Arroyo Varela(Malaga, Spain)
COI
17
LSC - 2021 - Regulation of PA200 in lung cancer
A. Yazgili(München, Germany)
COI
18
Efficiency of carbon nano tube (CNT) capture of blood circulating lung cancer cells
R. Yung(Owings Mills, United States)
COI
19
. . .